A Brief Mind-Body Bridging Intervention for Suicidal Ideation

Overview

The aim of this study is to determine whether a Brief Mind-Body Bridging Intervention for Suicidal Ideation (MBB-SI) will result in short or longer-term reduction of psychological factors associated with suicidal ideation (SI) and/or suicide-related behaviors (SRB's) compared to Treatment as Usual (TAU).

Full Title of Study: “A Randomized Pilot Study of a Brief Mind-Body Bridging Intervention for Suicidal Ideation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 31, 2020

Interventions

  • Behavioral: Mind Body Bridging Group Session
    • Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.

Arms, Groups and Cohorts

  • No Intervention: Treatment as Usual (TAU)
    • Participants assigned to Treatment As Usual (TAU) will receive the normal standard of care treatment from the Suicide Prevention Team and the Mental Health Service which may include individual therapy, group therapy, and/or medication therapy, all as decided by the individual and his/her doctor. Treatment as usual also includes monitoring by the Suicide Prevention Team.
  • Experimental: Treatment As Usual with Mind-Body Bridging (TAU + MBB)
    • Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator.

Clinical Trial Outcome Measures

Primary Measures

  • Change in frequency and/or intensity of suicidal ideation
    • Time Frame: Weekly during the intervention, one-month post-intervention, three months post-intervention, six months post-intervention
    • Determine if there is a significant difference in the frequency and/or intensity of suicidal ideation, as measured by the Beck Scale for Suicide Ideation (BSS) among the MBB-SI + TAU cohort compared to the TAU. We will use the total BSS score, ranging from 0 to 38. Increased scores reflect greater suicide risk.

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects will be Veterans aged 18-70 with psychiatric and/or addictive disorders who are on the High Risk Suicide List because of suicidal ideations and/or behaviors.

Exclusion Criteria

  • Diagnosis of psychotic spectrum illness and current psychotic symptoms or significant cognitive impairment.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • VA Salt Lake City Health Care System
  • Collaborator
    • Mind Body Bridging Charity
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Don Glover, PhD, Principal Investigator, VA Salt Lake City HCS
  • Overall Contact(s)
    • Don Glover, PhD, 8015821565, don.glover@va.gov

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.